June 29, 2020 / 5:34 AM / 17 days ago

BRIEF-Nordic Nanovector Betalutin Receives Fast-Track Designation From US FDA

June 29 (Reuters) - Nordic Nanovector ASA:

* NORDIC NANOVECTOR’S BETALUTIN® RECEIVES FAST-TRACK DESIGNATION FROM US FDA

* US FOOD AND DRUG ADMINISTRATION (FDA) GRANTS FAST TRACK DESIGNATION FOR INVESTIGATING BETALUTIN ( LU LILOTOMAB SATETRAXETAN) FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL)

* IS EVALUATING OPPORTUNITY TO DEVELOP BETALUTIN® AS A SINGLE-AGENT TREATMENT FOR MZL, A RARE TYPE OF NON-HODGKIN’S LYMPHOMA (NHL)

* BETALUTIN® HAS DEMONSTRATED A VERY PROMISING CLINICAL EFFECT IN NINE MZL PATIENTS IN PHASE 1/2A LYMRIT 37-01 TRIAL Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below